Sign In
Free Newsletter
Viela Bio begins clinical trials months after $250M spinoff
One of Maryland‘s best-funded biotech companies took a milestone first step Monday, announcing it has begun clinical trials of a medication it is developing. Gaithersburg-based Viela Bio was spun out of MedImmune, […]
With $250M from investors, Viela Bio out on its own
MedImmune spun out Viela Bio as an independent biotechnology company with $250 million in Series A financing and six potential medicines, the companies announced Wednesday. Viela Bio will be based […]
JHU to offer new Ph.D program with biomedical firm
Johns Hopkins University is launching a new Ph.D program that will offer students hands-on work experience in the biopharmaceutical field, where they’ll learn about the process of discovering and developing […]
Frederick approves MedImmune expansion, road improvements
FREDERICK — The city of Frederick has finalized a loan package that will approve expansion of MedImmune‘s Frederick biotech manufacturing plant and improve roads around the business. The Frederick News-Post […]
Plant’s expansion to continue with Md. county’s support
FREDERICK — The Frederick County Council has voted to financially support the expansion of MedImmune‘s Frederick manufacturing plant, a project the company says will bring 300 new jobs. The Frederick […]
MedImmune certified for energy program
Gaithersburg-based MedImmune, the biologics research and development arm of AstraZeneca, has been certified by the Department of Energy’s Superior Energy Performance program for improvements at its headquarters facility. MedImmune is […]
MedImmune expands partnership with USM
Gaithersburg-based MedImmune is expanding its recently announced research partnership with the University of Maryland, Baltimore to include two more UM campuses: College Park and Baltimore County.
MedImmune inks deal
Gaithersburg-based MedImmune has entered into a three-year partnership with the Clinical and Translational Science Institute at the University of California, San Francisco.
UMB, MedImmune agree to collaborate
The University of Maryland, Baltimore and MedImmune Inc., of Gaithersburg, a subsidiary of British drug maker AstraZeneca PLC, announced they have entered into a five-year, $6 million agreement to work on novel bioscience research in Maryland.
AstraZeneca reorganization to cut 1,600 jobs, move 300 to Gaithersburg
TRENTON, N.J. — Struggling Anglo-Swedish drugmaker AstraZeneca PLC said Monday that it will eliminate 1,600 jobs, mostly in the U.S. and United Kingdom, as its new CEO starts a major […]
Jallal named to UM Health Sciences Research Park board
Bahija Jallal, Ph.D., executive vice president of research and development at MedImmune, has been named to the board of directors of the UM Health Sciences Research Park Corp. Jallal is […]
O’Malley to bring more than 100 on trade mission to India
Gov. Martin O’Malley will embark on a trade mission to India, the first by a sitting Maryland governor, at the end of November with a delegation of more than 100 […]
